The role of outdoor activity in myopia prevention.

L. Deng, Yi Pang
{"title":"The role of outdoor activity in myopia prevention.","authors":"L. Deng, Yi Pang","doi":"10.21037/JES.2016.04.04","DOIUrl":null,"url":null,"abstract":"Myopia, also known as nearsightedness, is the most common vision disorder among children and young adults. In the last several decades, the prevalence of myopia has surged in East Asia. In some industrialized regions it has already reached an epidemic level (1,2). A smaller increase in the prevalence has also been observed in Western countries (2,3). The cost of visual aids or corrections put a great financial burden on individuals, families and the health care system. Myopia is not just an optical inconvenience. Early onset myopia is often accompanied with fast progression and very likely it will end up with high myopia (higher than 6.00 D myopia). High myopia poses a higher risk for developing glaucoma, retinal detachments and other vision threatening conditions. As our understanding of myopia was and is still poor, the research and development of an effective and safe tool in controlling myopia has been moving forward slowly. The current options for slowing down myopia progression include applying pharmaceutical agents such as atropine, wearing corrections with special optical design including bifocal spectacles, dual-focal contact lenses, and orthokeratology (ortho-K) (4). The most effective treatment up-to-date is 1% atropine, with well-established clinically relevant efficacy. However, the side-effect of long-term use and rebound effect after discontinuation of atropine were major concerns. Recently published results from a study conducted in Singapore clearly showed that atropine at a much lower dosage 0.01% could slow down myopia progression in children though its treatment size was smaller compared to the higher dosage levels: 1.0%, 0.5% and 0.1% (5). In addition, their results indicated that the group with 0.01% atropine had little rebound after cessation of the treatment while the other groups progressed much faster than the control group. More investigations on this promising strategy are still ongoing. Another promising option is ortho-K contact lenses. The benefit of wearing ortho-K in retarding axial elongation has been confirmed by randomized clinical trials (RCTs) (6). Prescribing contact lenses in very young children is still non-conventional due to hygiene and safety concerns. Other optical correction methods include multifocal and bifocal spectacles. Multifocal/bifocal spectacle provides minimal myopia control effect: statistically significant but without clinical significance (4). Finally, none of these intervention methods had been studied for a long period of time (>5 years) and thus their long-term effect is unknown. Unlike studies on retarding myopia progression, publications on myopia prevention methods are rarely seen in literature.","PeriodicalId":12096,"journal":{"name":"眼科学报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/JES.2016.04.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Myopia, also known as nearsightedness, is the most common vision disorder among children and young adults. In the last several decades, the prevalence of myopia has surged in East Asia. In some industrialized regions it has already reached an epidemic level (1,2). A smaller increase in the prevalence has also been observed in Western countries (2,3). The cost of visual aids or corrections put a great financial burden on individuals, families and the health care system. Myopia is not just an optical inconvenience. Early onset myopia is often accompanied with fast progression and very likely it will end up with high myopia (higher than 6.00 D myopia). High myopia poses a higher risk for developing glaucoma, retinal detachments and other vision threatening conditions. As our understanding of myopia was and is still poor, the research and development of an effective and safe tool in controlling myopia has been moving forward slowly. The current options for slowing down myopia progression include applying pharmaceutical agents such as atropine, wearing corrections with special optical design including bifocal spectacles, dual-focal contact lenses, and orthokeratology (ortho-K) (4). The most effective treatment up-to-date is 1% atropine, with well-established clinically relevant efficacy. However, the side-effect of long-term use and rebound effect after discontinuation of atropine were major concerns. Recently published results from a study conducted in Singapore clearly showed that atropine at a much lower dosage 0.01% could slow down myopia progression in children though its treatment size was smaller compared to the higher dosage levels: 1.0%, 0.5% and 0.1% (5). In addition, their results indicated that the group with 0.01% atropine had little rebound after cessation of the treatment while the other groups progressed much faster than the control group. More investigations on this promising strategy are still ongoing. Another promising option is ortho-K contact lenses. The benefit of wearing ortho-K in retarding axial elongation has been confirmed by randomized clinical trials (RCTs) (6). Prescribing contact lenses in very young children is still non-conventional due to hygiene and safety concerns. Other optical correction methods include multifocal and bifocal spectacles. Multifocal/bifocal spectacle provides minimal myopia control effect: statistically significant but without clinical significance (4). Finally, none of these intervention methods had been studied for a long period of time (>5 years) and thus their long-term effect is unknown. Unlike studies on retarding myopia progression, publications on myopia prevention methods are rarely seen in literature.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
户外活动在近视预防中的作用。
近视,也被称为近视,是儿童和年轻人中最常见的视力障碍。在过去的几十年里,近视的发病率在东亚急剧上升。在一些工业化区域,它已经达到流行病的程度(1,2)。在西方国家也观察到患病率有较小的增加(2,3)。视觉辅助或矫正的费用给个人、家庭和卫生保健系统带来了巨大的经济负担。近视不仅仅是视觉上的不便。早发性近视通常伴有快速发展,很可能最终发展为高度近视(高于6.00 D的近视)。高度近视会增加青光眼、视网膜脱离和其他视力威胁疾病的风险。由于我们对近视的认识过去和现在仍然很差,有效、安全的控制近视工具的研究和开发进展缓慢。目前减缓近视进展的选择包括使用阿托品等药物,佩戴特殊光学设计的矫正眼镜,包括双焦点眼镜、双焦点隐形眼镜和角膜塑形术(ortho-K)(4)。目前最有效的治疗方法是1%阿托品,具有良好的临床相关疗效。然而,长期使用阿托品的副作用和停药后的反弹效应是主要的问题。新加坡最近发表的一项研究结果清楚地表明,0.01%的低剂量阿托品可以减缓儿童近视的进展,尽管其治疗规模比1.0%、0.5%和0.1%的高剂量阿托品要小(5)。此外,他们的结果表明,0.01%的阿托品组在停止治疗后几乎没有反弹,而其他组的进展速度比对照组快得多。关于这一有前途的战略的更多调查仍在进行中。另一个有希望的选择是orthok隐形眼镜。随机临床试验(rct)证实了佩戴orthok在延缓轴向伸长方面的益处(6)。由于卫生和安全方面的考虑,在非常年幼的儿童中处方隐形眼镜仍然是非常规的。其他光学校正方法包括多焦点和双焦点眼镜。多焦/双焦眼镜控制近视的效果最小:具有统计学意义,但没有临床意义(4)。最后,这些干预方法都没有经过长时间(>5年)的研究,因此其长期效果尚不清楚。与延缓近视进展的研究不同,有关近视预防方法的出版物在文献中很少见到。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
1312
期刊介绍: Eye science was founded in 1985. It is a national medical journal supervised by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and hosted by Sun Yat-sen University Zhongshan Eye Center (in October 2020, it was changed from a quarterly to a monthly, with the publication number: ISSN: 1000-4432; CN: 44-1119/R). It is edited by Ge Jian, former dean of Sun Yat-sen University Zhongshan Eye Center, Liu Yizhi, director and dean of Sun Yat-sen University Zhongshan Eye Center, and Lin Haotian, deputy director of Sun Yat-sen University Zhongshan Eye Center, as executive editor. It mainly reports on new developments and trends in the field of ophthalmology at home and abroad, focusing on basic research in ophthalmology, clinical experience, and theoretical knowledge and technical operations related to epidemiology. It has been included in important databases at home and abroad, such as Chemical Abstract (CA), China Journal Full-text Database (CNKI), China Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Journal Database (VIP).
期刊最新文献
Uveitis secondary to cancer therapeutics Optical coherence tomography angiography of non-exudative choroidal neovascularization. Application of visual electrophysiology for the diagnosis and treatment of cataracts. Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy. Approved pharmacotherapy for myopic choroidal neovascularization: a review of randomized controlled trials in ranibizumab and aflibercept.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1